Business Wire

TX-RAPID-MEDICAL

15.5.2024 10:04:32 CEST | Business Wire | Press release

Share
Rapid Medical™ Completes Successful Ischemic Stroke Procedures with the World’s First Robotic Thrombectomy Device

Rapid Medical™, a leading developer of advanced neurovascular devices, announces the first successful robotic thrombectomy in Medellín, Colombia. Two patients were treated with the Robotic TIGERTRIEVER™, the first endovascular thrombectomy device that adapts autonomously to the patient’s anatomy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513456936/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The AI-powered TIGERTRIEVER removes stroke-causing blood clots during first-in-man procedures in Colombia. Rapid Medical’s portfolio of active technology allows greater procedural personalization, which is enhanced with AI workflow. (Photo: Business Wire)

“Automating stroke procedures is a significant advancement for the medical field,” emphasizes Dr. Boris Pabón, the endovascular neurosurgeon at Angiosur who performed the first-in-man procedures. “Robotic clot removal achieves a level of precision that surpasses interventional capabilities. The robotic TIGERTRIEVER gives me direct insight into the vessel characteristics and senses what I cannot–truly remarkable.”

With the press of a button, the AI-activated TIGERTRIEVER captures the blockage with active integration. The device’s radial force is then automatically reduced to minimize trauma to the brain as it is retrieved. This builds upon the excellent clinical results and procedure times seen with TIGERTRIEVER’s adjustability, further enhancing precision and streamlining workflow.

“Implementing this technology is a testament to our commitment to expanding treatment for stroke patients worldwide,” affirms Ronen Eckhouse, CEO of Rapid Medical. “We are at the forefront of advancing care—first by providing physicians with active technology and now paving a new pathway to automate procedures with intelligent control.”

About Rapid Medical

Rapid Medical expands what’s possible in neurovascular treatment by pioneering advanced interventional devices that treat ischemic and hemorrhagic stroke. Utilizing proprietary manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real time to the anatomy and tailor the approach to every patient for better procedural outcomes. TIGERTRIEVER™ 13, 17, and 21, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER XL is also CE marked. More information is available at www.rapid-medical.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513456936/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release

Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release

Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release

ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa

Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release

Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the

Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release

Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye